Bridgette Galafa

Bridgette Galafa

Auto-generated profile, based on publicly available information

Bridgette Galafa

MARVELS, Clinical and Experimental Medicine, Malawi-Liverpool Wellcome Research Programme , Blantyre

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
BGBridgette Galafa
Bridgette Galafa
TCTarsizio Chikaonda
Tarsizio Chikaonda
EKEvaristar Kudowa
Evaristar Kudowa
SSSimon Sichone
Simon Sichone
LSLusako Sibale
Lusako Sibale
SGStephen B Gordon
Stephen B Gordon
In Malawi, the national 13-valent pneumococcal conjugate vaccine (PCV13) demonstrated less herd immunity than in the United States, likely due to higher natural pneumococcal carriage rates. We assessed PCV13 efficacy against experimental pneumococcal carriage in healthy Malawian adults. We explored how natural carriage (pneumococcal carriage of any serotype apart from 6B) influenced experimental carriage rates and vaccine efficacy. Healthy adults aged 18 to 40 years were randomly assigned to PCV13 (n = 98) or saline (n = 106), followed by intranasal SPN 6B inoculation at 20 000 (n = 40), 80 000 (n = 74), or 160 000 (n = 90) colony-forming units/100 µL at 28 days postvaccination. We evaluated natural and experimental pneumococcal carriage before and after vaccination on days 2, 7, and 14 postinoculation using culture and multiplex quantitative polymerase chain reaction (qPCR) targeting the lytA/cpsA genes, and we compared carriage rates by vaccination status. Of 204 participants, 19.6% (n = 40) exhibited experimental carriage detected by culture and 25.5% (n = 52) by qPCR. Vaccinated individuals had lower experimental carriage rates (10.2%, n = 10/98) than the placebo group (28.3%, 30/106). This difference in vaccine efficacy was more pronounced in participants without natural carriage (PCV13, 8%, 6/75; placebo, 25.9%, 21/81) vs those with natural carriage (PCV13, 14.8%, 4/27; placebo, 26.5%, 9/34). According to a log-binomial model, vaccine effectiveness (VE) was 62%, whether assessed by culture or qPCR. Natural carriers had lower VE (52%) vs participants with no natural carriage (69%). We have shown that the PCV13 VE estimate (62%) is robust whether carriage is assessed by culture or qPCR. PCV13 had lower VE in natural carriers when compared with those without natural carriage at the inoculation visit.

4 April 2024 in Vaccine
Verified
Journal Article
Open access
GTG. Tembo
G. Tembo
MMM. Mayuni
M. Mayuni
RKR. Kamng'ONa
R. Kamng'ONa
LCL. Chimgoneko
L. Chimgoneko
GCG. Chiwala
G. Chiwala
KJK.C. Jambo
K.C. Jambo
Pneumococcal carriage is the primary reservoir for transmissionand a prerequisite for invasive pneumococcal disease. Pneumococcal Conjugate Vaccine 13 (PCV13) showed a 62% efficacy in protection against experimental Streptococcus pneumoniae serotype 6B (Spn6B) carriage in a controlled human infection model (CHIM) of healthy Malawian adults. We, therefore, measured humoral responses to experimental challenge and PCV-13 vaccination and determined the association with protection against pneumococcal carriage. We vaccinated 204 young, healthy Malawian adults with PCV13 or placebo and nasally inoculated them with Spn6B at least four weeks post-vaccination to establish carriage. We collected peripheral blood and nasal lining fluid at baseline, 4 weeks post-vaccination (7 days pre-inoculation), 2, 7, 14 and > 1 year post-inoculation. We measured the concentration of anti-serotype 6B Capsular Polysaccharide (CPS) Immunoglobulin G (IgG) and IgA antibodies in serum and nasal lining fluid using the World Health Organization (WHO) standardised enzyme-linked immunosorbent assay (ELISA). PCV13-vaccinated adults had higher serum IgG and nasal IgG/IgA anti-Spn6B CPS-specific binding antibodies than placebo recipients 4 to 6 weeks post-vaccination, which persisted for at least a year after vaccination. Nasal challenge with Spn6B did not significantly alter serum or nasal anti-CPS IgG binding antibody titers with or without experimental pneumococcal carriage. Pre-challenge titers of PCV13-induced serum IgG and nasal IgG/IgA anti-Spn6B CPS binding antibodies did not significantly differ between those that got experimentally colonised by Spn6B compared to those that did not. This study demonstrates that despite high PCV13 efficacy against experimental Spn6B carriage in young, healthy Malawian adults, robust vaccine-induced systemic and mucosal anti-Spn6B CPS binding antibodies did not directly relate to protection.

13 August 2024 in Wellcome Open Research
Verified
Journal Article
Open access
TCT Chikaonda
T Chikaonda
ACAnthony Emeritus Chirwa
Anthony Emeritus Chirwa
GLGareth Lipunga
Gareth Lipunga
FTFaith Thole
Faith Thole
BGBridgette Galafa
Bridgette Galafa
SGStephen B. Gordon
Stephen B. Gordon
Background Streptococcus pneumoniae is a major cause of morbidity and mortality from respiratory tract infections, pneumonia, meningitis, and sepsis. Nasopharyngeal carriage of pneumococcus is a prerequisite for pneumococcal disease and transmission. Since the global introduction of pneumococcal conjugated vaccines, rates of pneumococcal disease have declined for many vaccine type serotypes but serotype 3 (SPN3) continues to cause significant disease. The Experimental Human Pneumococcal Challenge (EHPC) model is a unique method of determining pneumococcal colonisation, understanding the impact of colonisation on acquired immunity and for testing pneumococcal vaccines. This study will develop a serotype 3 EHPC model to address some pertinent questions on the burden of pneumococcal disease in Malawi. Methods Healthy adults aged 18-50 years will be recruited, with a maximum target of 83 participants to complete all study visits. The study will consist of a dose ranging and safety study, followed by a reproducibility study. Sequential cohorts of 10 healthy participants will be challenged with escalating doses of SPN3 in the dose ranging study. Samples will be collected before inoculation and on days 2, 7, 13, 16, 21 and 28 following inoculations, for determination of carriage. A total of 33 participants will be enrolled in the reproducibility part and will use a dose that established ≥60% of carriage, and with a high safety profile. Samples will be collected for determination of both local and systemic immunological responses to pneumococcal challenge. Upon completion of study visits, participants will complete a questionnaire establish acceptability. Interpretations We expect to establish an optimal SPN3 dose required to establish nasopharyngeal colonisation in healthy adults in an EHPC model. The model can then be used to evaluate pneumococcal vaccines in both healthy and at-risk populations.

15 October 2026 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
KDKlara Doherty
Klara Doherty
JHJosh Hamilton
Josh Hamilton
TNTiyamike Nthandira
Tiyamike Nthandira
ACAnthony E Chirwa
Anthony E Chirwa
GTGodwin Tembo
Godwin Tembo
VKVusumuzi Katangwe
Vusumuzi Katangwe
Background: People with human immunodeficiency virus (HIV) in sub-Saharan Africa remain at high risk of pneumococcal carriage and disease, despite effective antiretroviral therapy. Understanding the immune factors driving this is key to addressing the issue. Methods: Virally suppressed, clinically stable people with HIV (PWH; n = 60) and HIV-uninfected adults (n = 60) underwent intranasal challenge with live pneumococcal serotype 6B. Experimental carriage was determined by culture and serotyping of nasal wash samples. Pneumococcal capsular and whole-cell immunoglobulin G (IgG) in nasal wash and serum samples were measured by enzyme-linked immunosorbent assay. Antibody binding was measured using a flow cytometry assay. Results: Baseline pneumococcal capsular IgG, whole-cell IgG, and antibody binding were similar between PWH and HIV-uninfected participants. Challenge did not increase IgG concentration in either group. Carriage susceptibility among PWH was associated with lower baseline serum capsular 6B IgG (0.84 vs 2.33 µg/mL, P < .01), lower nasal capsular 6B IgG (328 vs 761 pg/mL, P = .07), and lower nasal whole-cell IgG (92.2 vs 205 AU/mL, P = .02). These associations were not observed in HIV-uninfected participants. Carriage in HIV-uninfected participants was associated with an increase in IgG binding from baseline to day 21 (120 vs 209 AU, Friedman χ2 = 11.1, P = .004), which was not detected in PWH (79.2 vs 72.3 AU, χ2 = 0.67, P = .72). Conclusions: Baseline pneumococcal IgG levels and function were similar in PWH and HIV-uninfected participants. However, experimental challenge revealed specific differences in humoral correlates of pneumococcal carriage between PWH and HIV-uninfected adults. These findings support evaluation of vaccination strategies to enhance pneumococcal antibody concentration and function in PWH in sub-Saharan Africa.

17 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JNJohn Ndaferankhande
John Ndaferankhande
KJKondwani Jambo
Kondwani Jambo
TCTarsizio Chikaonda
Tarsizio Chikaonda
GTGodwin Tembo
Godwin Tembo
LCLaura Conejero
Laura Conejero
SGStephen B. Gordon
Stephen B. Gordon
Background: Bacterial mucosal immunotherapy has shown protection of children and adults from both viral and bacterial respiratory infections, offering the potential to reduce antimicrobial use, and hence also control antimicrobial resistance (AMR). Pneumococcal carriage of vaccine type S. pneumoniae remains high in Malawi despite infant conjugate vaccination and AMR is increasing. We compared nasal inflammation following sublingual bacterial immunotherapy (MV130, Immunotek, Spain) or placebo and determined the effect in an experimental human pneumococcal carriage model.Methods: A double-blind, randomized, placebo-controlled trial in healthy adult volunteers was conducted at Queen Elizabeth Central Hospital in Blantyre, Malawi. Participants were randomly allocated to receive MV130 or placebo sublingually once daily for 42 days. Mucosal inflammation (neutrophil to T cell ratio) was measured in nasal micro-biopsies. Post-treatment, participants were challenged with 80,000 CFU/naris Streptococcus pneumoniae 6B (SPN6B). Experimental pneumococcal carriage rates post inoculation were compared between the two arms. All participants completing the study were included in the analysis. Trial Registration: Pan African Clinical Trial Registry: PACTR202403820001276.Findings: 107 participants were enrolled and randomized to MV130/placebo between May and December 2024. There were no serious adverse events, and all adverse events were mild. 96 participants (53 male, 43 female) completed the study with 52 participants randomized to MV130 and 44 to placebo. There was no difference in mucosal inflammation (neutrophil to T cell ratio) at day 14 with the intervention MV130 NTR median = 0.737 (IQR 0.294,2.059) and placebo NTR = 0.831 (IQR 0.450,2.073), p=0.64. On day 35 of MV130 treatment NTR median=1.565 compared to placebo NTR=0.820, p=0.01. There was no difference in experimental pneumococcal carriage proportion between MV130 (12/52, 23%) and placebo (10/44, 23%) groups (p=1.0). Interpretation: MV130 induced mild neutrophil inflammation of the nasal mucosa but had no protective effect against experimental human pneumococcal carriage.